The BCG Vaccine is a vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.
The century-old Bacille Calmette-Guérin (BCG) vaccine against tuberculosis is one of the world's oldest and most widely used vaccines, used to immunize 100 million newborns every year. Given in countries with endemic TB, it has surprisingly been found to protect newborns and young infants against multiple bacterial and viral infections unrelated to TB. There's even some evidence that it can reduce severity of COVID-19.
In a recent study posted to the bioRxiv* preprint server, the researchers investigated the impact of Bacillus Calmette-Guérin (BCG) vaccine-induced antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein.
Researchers tested the effectiveness of the BCG vaccine in SARS-CoV-2-infected Syrian hamsters.
We speak to Dr. Alemnew Dagnew from the Bill & Melinda Gates Medical Research Institute, about their tuberculosis vaccine study and the future of tuberculosis.
Briefly blocking a key molecule when administering the only approved vaccine for tuberculosis vastly improves long-term protection against the devastating disease in mice, researchers from Texas Biomedical Research Institute report this week in the Journal of Immunology.
Researchers at Massachusetts General Hospital, in partnership with NYU Langone Health, have launched a multi-center clinical trial to investigate a new treatment for pediatric type 1 diabetes even in subjects with established disease.
Researchers investigated the effectiveness of the BCG vaccines against SARS-CoV-2 infections using three animal models.
A new paper finds that the influenza vaccine may influence both the response to and incidence of infection by the SARS-CoV-2.
A recent US study, currently available on bioRxiv* preprint server, implies that vaccination with bacille Calmette-Guérin (BCG) can limit the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by targeting innate immune pathways and could thus be used as a platform for pinpointing early immunologic events affecting the outcome of coronavirus disease (COVID-19).
A new study estimates vaccine effectiveness against COVID-19 mortality in England using the RDD approach.
At the recent 2021 Annual Scientific Sessions of the American Diabetes Association, researchers from Massachusetts General Hospital (MGH) presented positive updates on their trials of the bacillus Calmette-Guérin (BCG) vaccine to safely and significantly lower blood sugars.
Tuberculosis is one of the top ten causes of death worldwide, infecting about one-quarter of the world's population. Although it is treatable, the rise of multidrug-resistant tuberculosis poses a major threat to global health security, and has been declared by the World Health Organization as a global health emergency.
An Australian-led study will investigate whether it's possible to predict who remains susceptible to SARS-CoV-2 variants after having COVID-19 or receiving a COVID-19-specific vaccine.
Varying immune response to vaccinations could be countered with microbiota-targeted interventions helping infants, older people and others to take full advantage of the benefits of effective vaccines, Australian and US experts say.
A considerably higher dose of the anti-tuberculosis drug rifampicin is safe and can also lead to a shorter treatment for tuberculosis and less resistance.
St Petersburg University scientists have analyzed about 100 academic papers and statistics on the incidence of COVID-19 in different countries of the world.
Differences in the immune systems and better blood vessel health were among the factors protecting children from severe COVID-19, according to a new review.
Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.
COVID-19 continues to wreak havoc globally, with over one million deaths to date. Yet what if an existing vaccine could make COVID-19 less deadly? A study just published put the theory to test, with promising results.
Researchers from Mayo Clinic, United States of America, have reviewed the immunity developed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.